These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 24498562)

  • 1. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8
    Strachan DC; Ruffell B; Oei Y; Bissell MJ; Coussens LM; Pryer N; Daniel D
    Oncoimmunology; 2013 Dec; 2(12):e26968. PubMed ID: 24498562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSF1/CSF1R Axis Blockade Limits Mesothelioma and Enhances Efficiency of Anti-PDL1 Immunotherapy.
    Magkouta SF; Vaitsi PC; Pappas AG; Iliopoulou M; Kosti CN; Psarra K; Kalomenidis IT
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34067348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual inhibition of CSF1R and MAPK pathways using supramolecular nanoparticles enhances macrophage immunotherapy.
    Ramesh A; Brouillard A; Kumar S; Nandi D; Kulkarni A
    Biomaterials; 2020 Jan; 227():119559. PubMed ID: 31670078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rational combination of an immune checkpoint inhibitor with CSF1R inhibitor-loaded nanoparticle enhances anticancer efficacy.
    Ramesh A; Malik V; Ranjani HA; Smith H; Kulkarni AA
    Drug Deliv Transl Res; 2021 Dec; 11(6):2317-2327. PubMed ID: 34365577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy.
    Gyori D; Lim EL; Grant FM; Spensberger D; Roychoudhuri R; Shuttleworth SJ; Okkenhaug K; Stephens LR; Hawkins PT
    JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of tumor-derived colony-stimulating factor 1 (CSF1) promotes an immune-permissive tumor microenvironment.
    Maldonado MDM; Schlom J; Hamilton DH
    Cancer Immunol Immunother; 2023 Oct; 72(10):3349-3362. PubMed ID: 37505292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silence of a dependence receptor CSF1R in colorectal cancer cells activates tumor-associated macrophages.
    Zhu M; Bai L; Liu X; Peng S; Xie Y; Bai H; Yu H; Wang X; Yuan P; Ma R; Lin J; Wu L; Huang M; Li Y; Luo Y
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depletion of tumor-associated macrophages enhances the anti-tumor effect of docetaxel in a murine epithelial ovarian cancer.
    Lu X; Meng T
    Immunobiology; 2019 May; 224(3):355-361. PubMed ID: 30926154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSF1R inhibition reprograms tumor-associated macrophages to potentiate anti-PD-1 therapy efficacy against colorectal cancer.
    Lv Q; Zhang Y; Gao W; Wang J; Hu Y; Yang H; Xie Y; Lv Y; Zhang H; Wu D; Hu L; Wang J
    Pharmacol Res; 2024 Apr; 202():107126. PubMed ID: 38432446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.
    DeNardo DG; Brennan DJ; Rexhepaj E; Ruffell B; Shiao SL; Madden SF; Gallagher WM; Wadhwani N; Keil SD; Junaid SA; Rugo HS; Hwang ES; Jirström K; West BL; Coussens LM
    Cancer Discov; 2011 Jun; 1(1):54-67. PubMed ID: 22039576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macrophage-colony stimulating factor (CSF1) predicts breast cancer progression and mortality.
    Richardsen E; Uglehus RD; Johnsen SH; Busund LT
    Anticancer Res; 2015 Feb; 35(2):865-74. PubMed ID: 25667468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CSF1/CSF1R signaling mediates malignant pleural effusion formation.
    Kosti CN; Vaitsi PC; Pappas AG; Iliopoulou MP; Psarra KK; Magkouta SF; Kalomenidis IT
    JCI Insight; 2022 Mar; 7(6):. PubMed ID: 35315360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of CSF1R-targeted chimeric antigen receptor-modified NK92MI & T cells on tumor-associated macrophages.
    Zhang P; Zhao S; Wu C; Li J; Li Z; Wen C; Hu S; An G; Meng H; Zhang X; Yang L
    Immunotherapy; 2018 Aug; 10(11):935-949. PubMed ID: 30149762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1R.
    Czako B; Marszalek JR; Burke JP; Mandal P; Leonard PG; Cross JB; Mseeh F; Jiang Y; Chang EQ; Suzuki E; Kovacs JJ; Feng N; Gera S; Harris AL; Liu Z; Mullinax RA; Pang J; Parker CA; Spencer ND; Yu SS; Wu Q; Tremblay MR; Mikule K; Wilcoxen K; Heffernan TP; Draetta GF; Jones P
    J Med Chem; 2020 Sep; 63(17):9888-9911. PubMed ID: 32787110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of tumor-associated macrophage depletion by CSF1R blockade is highly dependent on the tumor model and timing of treatment.
    O'Brien SA; Orf J; Skrzypczynska KM; Tan H; Kim J; DeVoss J; Belmontes B; Egen JG
    Cancer Immunol Immunother; 2021 Aug; 70(8):2401-2410. PubMed ID: 33511454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer.
    Xu J; Escamilla J; Mok S; David J; Priceman S; West B; Bollag G; McBride W; Wu L
    Cancer Res; 2013 May; 73(9):2782-94. PubMed ID: 23418320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF1R signaling is a regulator of pathogenesis in progressive MS.
    Hagan N; Kane JL; Grover D; Woodworth L; Madore C; Saleh J; Sancho J; Liu J; Li Y; Proto J; Zelic M; Mahan A; Kothe M; Scholte AA; Fitzgerald M; Gisevius B; Haghikia A; Butovsky O; Ofengeim D
    Cell Death Dis; 2020 Oct; 11(10):904. PubMed ID: 33097690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colony-Stimulating Factor 1 Receptor (CSF1R) Activates AKT/mTOR Signaling and Promotes T-Cell Lymphoma Viability.
    Murga-Zamalloa C; Rolland DCM; Polk A; Wolfe A; Dewar H; Chowdhury P; Onder O; Dewar R; Brown NA; Bailey NG; Inamdar K; Lim MS; Elenitoba-Johnson KSJ; Wilcox RA
    Clin Cancer Res; 2020 Feb; 26(3):690-703. PubMed ID: 31636099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-Molecule CSF1R Inhibitors as Anticancer Agents.
    Xun Q; Wang Z; Hu X; Ding K; Lu X
    Curr Med Chem; 2020; 27(23):3944-3966. PubMed ID: 31215373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.